Activin A signaling in breast cancer: context-dependent reweighting of cytostatic, metastatic and immunomodulatory outputs

Activin A, a homodimeric ligand encoded by INHBA, is a pleiotropic member of the transforming growth factor-β superfamily whose effects in breast cancer depend on cellular and microenvironmental context. This review examines how ligand abundance and bioavailability, receptor composition, SMAD competence, transcriptional context, cellular source and the tumor microenvironment shape activin A signaling outputs. Importantly, INHBA expression, activin A protein abundance, extracellular ligand bioavailability and functional pathway activation represent distinct biological levels and should not be considered interchangeable. In selected epithelial contexts, activin A supports SMAD-dependent cytostasis and cell-cycle arrest, whereas in progression-associated contexts it is linked to epithelial plasticity, invasion, stem-like phenotypes, metastatic dissemination, stromal remodeling and immune regulation. We propose that the apparent activin A “signaling switch” represents context-dependent reweighting of signaling outputs rather than a binary molecular transition. Direct breast cancer evidence is strongest for cytostatic, EMT-associated and invasive phenotypes, whereas evidence for pro-angiogenic signaling, MMP2-dependent remodeling and some immunomodulatory effects remains more limited or context dependent. Activin A may also contribute to pulmonary metastatic progression through tumor-cell-intrinsic signaling and systemic conditioning of the lung microenvironment. Clinically, INHBA and activin A show prognostic or contextual associations but have not been validated as predictive biomarkers or therapeutic targets in breast cancer. Future studies should prioritize functional, cell-type-resolved and spatial biomarker strategies to distinguish cytostatic activin signaling from progression-associated activity.

Authors

Institutions

Publication Details

Journal
Breast Cancer Research
Published
2026-11-13
DOI
https://doi.org/10.1186/s13058-026-02406-5
Primary Topic
TGF-β signaling in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Activin A signaling in breast cancer: context-dependent reweighting of cytostatic, metastatic and immunomodulatory outputs

Cui Xueling, Wei Zhao, Baigong Xue, Xinyu Liu
Breast Cancer Research
TGF-β signaling in diseases
article

Activin A signaling in breast cancer: context-dependent reweighting of cytostatic, metastatic and immunomodulatory outputs

Cui Xueling, Wei Zhao, Baigong Xue, Xinyu Liu
article en

Abstract

Activin A, a homodimeric ligand encoded by INHBA, is a pleiotropic member of the transforming growth factor-β superfamily whose effects in breast cancer depend on cellular and microenvironmental context. This review examines how ligand abundance and bioavailability, receptor composition, SMAD competence, transcriptional context, cellular source and the tumor microenvironment shape activin A signaling outputs. Importantly, INHBA expression, activin A protein abundance, extracellular ligand bioavailability and functional pathway activation represent distinct biological levels and should not be considered interchangeable. In selected epithelial contexts, activin A supports SMAD-dependent cytostasis and cell-cycle arrest, whereas in progression-associated contexts it is linked to epithelial plasticity, invasion, stem-like phenotypes, metastatic dissemination, stromal remodeling and immune regulation. We propose that the apparent activin A “signaling switch” represents context-dependent reweighting of signaling outputs rather than a binary molecular transition. Direct breast cancer evidence is strongest for cytostatic, EMT-associated and invasive phenotypes, whereas evidence for pro-angiogenic signaling, MMP2-dependent remodeling and some immunomodulatory effects remains more limited or context dependent. Activin A may also contribute to pulmonary metastatic progression through tumor-cell-intrinsic signaling and systemic conditioning of the lung microenvironment. Clinically, INHBA and activin A show prognostic or contextual associations but have not been validated as predictive biomarkers or therapeutic targets in breast cancer. Future studies should prioritize functional, cell-type-resolved and spatial biomarker strategies to distinguish cytostatic activin signaling from progression-associated activity.

Breast Cancer Research
Jilin University (CN), First Hospital of Jilin University (CN)
Good health and well-being
TGF-β signaling in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon